10x Genomics (TXG) CEO Serge Saxonov Sells 25,000 Shares

What Happened
Serge Saxonov, CEO of 10x Genomics, sold a total of 25,000 shares in open‑market transactions on September 22, 2026. The reported sales were: 1,000 shares @ $78.23 ($78,228); 2,000 shares @ $79.62 ($159,239); 9,300 shares @ $80.90 ($752,401); 9,900 shares @ $81.83 ($810,071); and 2,800 shares @ $82.36 ($230,622), for aggregate proceeds of $2,030,561. These were sales (S), not purchases.

Key Details

• Transaction date: September 22, 2026; Form 4 filed September 24, 2026 (appears timely under Form 4 rules).
• Shares sold: 25,000 total; aggregate proceeds ≈ $2,030,561.
• Reported per‑trade weighted average prices as listed above; actual execution occurred in multiple trades at price ranges: $77.75–$78.73; $79.11–$80.07; $80.28–$81.27; $81.28–$82.25; and $82.28–$82.53 (see filing footnotes). The filer will provide per‑trade breakdown to the SEC or issuer on request.
• Sale executed pursuant to a Rule 10b5‑1 trading plan adopted November 29, 2025 (pre‑arranged plan).
• Footnotes indicate certain shares are held in trusts (Andromeda Trust, Y/S Descendants' Trust, Y/S Pot Trust) for which Saxonov serves as trustee.
• Shares owned after the transactions are not specified in the provided excerpt.

Context
Sales executed under a 10b5‑1 plan are typically pre‑planned and common for insiders to diversify or meet liquidity needs; they do not by themselves indicate the insider’s current view of the company. Purchases (insider buys) tend to be more indicative of bullish insider sentiment. The reporting person has committed to provide detailed per‑trade price/quantity information to the SEC or issuer on request.